What Will Most Differentiate the Next Generation of Obesity Medicines?

The obesity drug landscape is becoming more competitive, with oral therapies, multi-agonist candidates and new combinations joining established injectable GLP-1 medicines. Oral semaglutide is now FDA-approved for chronic weight management, adding another dosing option for adults with obesity or overweight.

As weight-loss outcomes improve across newer obesity therapies, developers are testing different ways to distinguish their candidates. 

In March 2026, the FDA approved a higher 7.2 mg dose of semaglutide for chronic weight management, extending the efficacy range of an established therapy. In July, Eli Lilly reported positive Phase III results for retatrutide, an investigational triple agonist targeting GLP-1, GIP and glucagon receptors, in patients with obesity or overweight and type 2 diabetes and in those with severe obesity and cardiovascular disease. These developments reflect a field examining both how much weight therapies can help patients lose and how they may perform across different patient populations and obesity-related conditions.

As treatment options expand, dosing convenience, tolerability and broader cardiometabolic outcomes could increasingly influence how obesity medicines are differentiated for clinicians and patients.

What do you think will matter most? Cast your vote below and join the conversation.

Got a poll idea you’d like us to feature? Share it with us!